EVISA Print | Glossary on | Contact EVISA | Sitemap | Home   
 Advanced search
The establishment of EVISA is funded by the EU through the Fifth Framework Programme (G7RT- CT- 2002- 05112).


Supporters of EVISA includes:

Publication on the separation of Gd-based contrast agents awarded

(25.03.2010)


The award, worth 2000 €, was given during the second day of 22nd International Trade Fair for Laboratory Technology, Analysis, Biotechnology and analytica Conference (analytica 2010) by Gerstel (represented by its executive directors Eberhard Gerstel and Holger Gerstel) and the GdCh working group "Separation Science" (represented by Klaus Bischoff and Prof. Dr. Werner Engewald).



Photo: (from left to right): Eberhard Gerstel, Holger Gerstel (executive directors Gerstel GmbH & Co. KG), Dr. Jens Künnemeyer, Klaus Bischoff (Chairman of the GDCh-Working Group Separation Science) and Prof. Dr. Werner Engewald (honorary chairman AK Separation Science) (Photo: GERSTEL)


Dr. Jens Künnemeyer was awarded for his work that was prepared during his doctorial thesis in the working group of Prof. Karst at the Institute for Inorganic and Analytical Chemistry of the University of Münster.  In search for a highly efficient method for the separation and determination of Gd-based contrast agents in samples such as waste water, Jens Künnemeyer had developed a method for ICP-MS based detection using HILIC for separation.  Gd-based contrast agents are used about 20,000,000 times a year for medical diagnosis using nuclear magnetic resonance imaging (NMRI). While free Gd is highly toxic, Gd in admitted Gd-based contrast agents is fixed in very stable complexes and therefore generally considered to be safe. However, in rare cases always related to renal failure patients, severe side effects resulting in Nephrogenic systemic fibrosis (NSF) have been observed. Besides such severe effects Jens Künnemeyer was also interested to study whether the stable Gd-complexes can still be found in hospital waste water receiving the urine from patients treated with the contrast agents. Using the developed HILIC-ICP-MS method, Künnemeyer was able to show that Gd-based contrast agents survive both human metabolism and waste water treatment.


The awarded publication

 Jens Künnemeyer, Lydia Terborg, Björn Meermann, Christine Brauckmann, Ines Möller, Andy Scheffer, Uwe Karst, Speciation Analysis of Gadolinium Chelates in Hospital Effluents and Wastewater Treatment Plant Sewage by a Novel HILIC/ICP-MS Method, Environ. Sci. Technol., 43/8 (2009) 2884-2890. DOI: 10.1021/es803278n


 Related EVISA Resources

 EVISA Link Database: Toxicity of Gadolinium compounds
 EVISA Materials Database: Gadolinium Materials
 EVISA Brief Summary: ICP-MS: A versatile detection system for speciation analysis
 EVISA Brief Summary: LC-ICP-MS: The most often used hyphenated system for speciation analysis
EVISA Company Database: Gerstel and their products


Related EVISA News (newest first)

March 14, 2016: Tracing Gadolinium-based Contrast Agents from Wastewater, via Surface Water to Drinking Water
March 4, 2015: Detection of Gd-based contrast agent in the skin of a patient eight years after administration
October 29, 2012: Identification and quantification of potential metabolites of Gd-based contrast agents 
October 18, 2012: The behavior of Gd-based contrast agents during wastewater treatment
September 15, 2010: US FDA Announces Gadolinium-Based MRI Contrast Agent Warning
May 4, 2009: Gadolinium speciation analysis in search for the cause of nephrogenic systemic fibrosis (NSF)
April 17, 2009: Gadolinium-based MRI contrast agents found intact in the outlet of a waste water treatment plant


last time modified: March 23, 2016



Comments






Imprint     Disclaimer

© 2003 - 2010 by European Virtual Institute for Speciation Analysis ( EVISA )